, China
/Beth Macdonald from Unsplash

China-based Groupama SDIG enhances non-agri insurance strategy

Over the past three years, the company’s combined ratio averaged 98%.

Whilst underwriting results from non-agricultural insurance were initially weak, China-based Groupama SDIG Property Insurance Co., Ltd. has improved through risk segmentation, tighter expense control, and product optimisation, Fitch Ratings said. 

However, impairment losses from premium receivables have constrained overall operating profitability during this period.  

Over the past three years, the company’s combined ratio averaged 98%, supported primarily by the strong performance of its agricultural insurance policies.  

Groupama SDIG operates in 12 provinces in China, with strongholds in regions like Sichuan and Jilin. Despite this, its market share in China’s non-life insurance market was just 0.2% in 2023, with agricultural insurance remaining its primary focus.  

As an "Important" operating subsidiary, Groupama SDIG benefits from support under the Groupama Group framework, per Fitch’s insurance group criteria. 

The company operates as a 50-50 joint venture between Groupama Group and Shudao Investment Group Co., Ltd (SDIG), marketing its products under the "Groupama SDIG" brand in China.
 

Follow the link for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.